R&D channel feed

Af­ter a con­tentious lead-up, Rob Califf like­ly to be con­firmed as FDA com­mis­sion­er next week

4 years ago

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the clin­ic

4 years ago

As­traZeneca picks win­ner in in­haled JAK 'bake-of­f' while sweep­ing Alex­ion drug out

4 years ago

In fi­nal analy­sis, J&J's un­der­dog vac­cine of­fers on­ly 52.9% pro­tec­tion against Covid-19

4 years ago
Coronavirus

Hal Bar­ron’s swan song as GSK R&D chief ends with a promise: The best is yet to come

4 years ago

With first hu­man da­ta, long-strug­gling Si­lence Ther­a­peu­tics leaps in­to next big car­dio­vas­cu­lar race

4 years ago

Tak­ing on Big Phar­ma-sized in­di­ca­tions, tiny biotech claims ear­ly win in fat loss. Will it trans­late to di­a­betes, NASH and be­yond?

4 years ago

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try in 2022? Nom­i­nate them for End­points' spe­cial re­port

4 years ago
People

An­a­lysts ques­tion Karyophar­m's PhI­II en­dome­tri­al can­cer da­ta as biotech will charge ahead to FDA

4 years ago

'Very over sol­d': Biotech brags about PhII Alzheimer's da­ta, but ex­perts are un­der­whelmed

4 years ago

AD­Cs in the pipeline: FDA spells out clin­i­cal phar­ma­col­o­gy musts for spon­sors

4 years ago
FDA+

With de­ci­sion loom­ing on J&J, Leg­end's CAR-T, an­a­lyst sees a new cham­pi­on emerg­ing in boom­ing BC­MA space

4 years ago

How re­searchers can get a han­dle on the mon­key short­age for tox stud­ies: FDA ex­plains

4 years ago
FDA+

Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ex­clu­siv­i­ty

4 years ago
Pharma

Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

4 years ago
Pharma

Pfiz­er lands on For­tune’s most ad­mired list, edg­ing out Dis­ney, Google and Star­bucks in an­nu­al rep­u­ta­tion rank­ing

4 years ago

Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

4 years ago

Watch out, As­traZeneca: UCB un­corks late-stage suc­cess for $2.1B Soliris ri­val

4 years ago

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

4 years ago
Deals

An­oth­er mi­cro­cap biotech plots ma­jor job cuts as in­dus­try sharp­ens its axe amid slow­down

4 years ago
People

'We need to do more': Mer­ck CEO Rob Davis high­lights M&A, deals strat­e­gy ahead of '28 Keytru­da patent cliff

4 years ago

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

4 years ago
Pharma

As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

4 years ago
Deals

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

4 years ago
News Briefing
First page Previous page 148149150151152153154 Next page Last page
A service from the Financial Times